Selenium-based drug design: rationale and therapeutic potential

Bibliography

• YOSHIZAWA K, WILLETT WC, MORRIS SJ et al.: Study of prediagnostic selenium level in toenails and the risk of advanced prostate cancer. J. Nati Cancer Inst. (1998) 90:1219–1224.
   PubMed Web of Science ®Google Scholar
• ••This recent study, which indicates that higher seleniumlevels are associated with a reduced risk of advanced prostate cancer, has attracted very wide media attention.
   Google Scholar
• SUBCOMMITTEE ON THE TENTH EDITION OF THERDA'S, FOOD AND NUTRITION BOARD, COMMISSION ON LIFE SCIENCES, NATIONAL RESEARCH COUNCIL: Recommended Dietary Allowances, Tenth Edition. National Academy Press, Washington DC, USA (1989).
   Google Scholar
• CLARK LC, COMBS GFJR, TURNBULL BW et al: Effect of selenium supplementation for cancer prevention in patients with carcinoma of the skin. J. Am. Med. Assoc. (1996): 276:1957–1963.
   Web of Science ®Google Scholar
• ••This paper is a landmark account of a long-term, double-blind, placebo-controlled study carried out in the USA, which showed that supplementation with dietary selenium markedly reduced the incidence of prostate, colorectal and lung cancer in humans.
   Google Scholar
• HUTTUNEN JK: Selenium and cardiovascular diseases - an update. Biomed. Environ. Sci. (1997) 10:220–226.
   PubMedGoogle Scholar
• KOSE K, DOGAN P, KARDAS Y et al.: Plasma selenium levels in rheumatoid arthritis. Biol. Trace Elem. Res. (1996) 53:51–56.
   PubMed Web of Science ®Google Scholar
• BAUM MK, SHOR-POSNER G, LAI S et al: High risk of HIV-related mortality is associated with selenium deficiency. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. (1997) 15:370–374.
   PubMed Web of Science ®Google Scholar
• FOX JM: Selenium: Nutritional implications and prospects for therapeutic medicine. Methods Find. Exp. Clin. Pharmacol (1992) 14:275–287.
   PubMed Web of Science ®Google Scholar
• PARNHAM MJ, GRAF E: Seleno-organic compounds and the therapy of hydroperoxide-linked pathological conditions. Biochem. Pharmacol (1987) 36:3095–3102.
   PubMed Web of Science ®Google Scholar
• BECK MA, SHI Q, MORRIS VC et al: Rapid genomic evolution of a non-virulent Coxsackievirus B3 in selenium-deficient mice results in selection of identical virulent isolates. Nature Med. (1995) 1:433–436.
   PubMed Web of Science ®Google Scholar
• ••In this remarkable paper, Beck et al. demonstrated that anon-virulent strain of Coxsackievirus mutates in selenium-deficient mice to produce a single genetic variant of the virus, which is now virulent.
   Google Scholar
• STADTMAN TC: Selenocysteine. Annu. Rev. Biochem. (1996) 65:83–100.
   PubMedGoogle Scholar
• •The biochemistry of selenocysteine incorporation and the distribution and properties of selenocysteine-containing enzymes and proteins are discussed in this review.
   Google Scholar
• URSINI F, BINDOLI A: The role of selenium peroxidases in the protection against oxidative damage of membranes. Chem. Phys. Lipids (1987) 44:255–276.
   PubMed Web of Science ®Google Scholar
• BARINAGA M: Vitamin C gets a little respect. Science (1991) 254:374–376.
   PubMed Web of Science ®Google Scholar
• HILL KE, BURK RF: Selenoprotein P - recent studies in rats and in humans. Biomed. Environ. Sci. (1997) 10:198–208.
   PubMedGoogle Scholar
• BURK RF, HILL KE, BOEGLIN ME et al: Selenoprotein Passociates with endothelial cells in rat tissues. Histochem. Cell Biol. (1997) 108:11–5.
   PubMed Web of Science ®Google Scholar
• HOLMGREN A, BJORNSTEDT M: Thioredoxin and thioredoxin reductase. Methods Enzymol. (1995) 252:199–208.
   PubMed Web of Science ®Google Scholar
• GLADYSHEV VN, JEANG KT, STADTMAN TC: Selenocys-teine, identified as the penultimate C-terminal residue in human T-cell thioredoxin reductase, corresponds to TGA in the human placental gene. Proc. Natl. Acad. Sci. USA (1996) 93:6146–6151.
   PubMed Web of Science ®Google Scholar
• •The finding that T-cell thioredoxin reductase is a selenoen-zyme possessing an Se moiety in its conserved C-terminal region, reported in this paper, demonstrates the key role of selenium in a major anti-oxidant enzyme system in addition to glutathione peroxidase.
   Google Scholar
• ZHONG L, ARN-ER ES, LJUNG J: Rat and calf thioredoxinreductase are homologous to glutathione reductase with a carboxyl-terminal elongation containing a conserved catalytically active penultimate selenocys-teine residue. J. Biol. Chem. (1998) 273:8581–8591.
   PubMed Web of Science ®Google Scholar
• WIMALASENA K, MAY SW: Ascorbic acid mediated N-dealkylation and N-deoxygenation of N,N-dimethylaniline N-oxide. J. Am. Chem. Soc. (1995) 117:2381–2386.
   Web of Science ®Google Scholar
• MAY JM, MENDIRATTA S, HILL KE et al.: Reduction ofdehydroascorbate to ascorbate by the selenoenzyme thioredoxin reductase. J. Biol. Chem. (1997) 272:22607–22610.
   PubMed Web of Science ®Google Scholar
• MAY JM, COBB CE, MENDIRATTA S et al.: Reduction of the Ascorbyl Free Radical to Ascorbate by Thioredoxin Reductase. J. Biol. Chem. (1998) 273:23039–23045.
   PubMed Web of Science ®Google Scholar
• BOCK A, FORCHHAMMER K, HEIDER J et al: Selenocys-teine: the 21st amino acid. Mol. Microbic)]. (1991) 5:515–520.
   PubMed Web of Science ®Google Scholar
• LEE SR, KIM JR, KWON KS et al.: Molecular cloning and characterization of a mitochondrial selenocysteine-containing thioredoxin reductase from rat liver. J. Biol. Chem. (1999) 274:4722–4734.
   PubMed Web of Science ®Google Scholar
• VERES Z, TSAI L, SCHOLZ TD et al.: Synthesis of 5-methylaminomethy1-2-selenouridine in tRNAs: 31P NMR studies show the labile selenium donor synthe-sized by the selD gene product contains selenium bonded to phosphorus. Proc. Natl. Acad. Sci. USA (1992) 89:2975–2979.
   PubMed Web of Science ®Google Scholar
• GLASS RS, SINGH WP, JUNG W et al.: Monoselenophos-phate: Synthesis, characterization, and identity with the procaryotic biological selenium donor, compound SePX. Biochemistry (1993) 32:12555–12559.
   PubMed Web of Science ®Google Scholar
• GELPI C, SONTHEIMER EJ, RODRIGUEZ-SANCHEZ JL:Autoantibodies against a serine tRNA-protein complex implicated in cotranslational selenocysteine insertion. Proc. Natl. Acad. ScL USA (1992) 89:9739–9743.
   PubMed Web of Science ®Google Scholar
• PAINTER, EP: The chemistry and toxicity of selenium compounds, with special reference to the selenium problem. Chem. Rev. (1941) 28:179–213.
   Google Scholar
• GANTHER HE: Selenotrisulfides. Formation by the reaction of thiols with selenious acid. Biochemistry (1968) 7:2898–2905.
   PubMed Web of Science ®Google Scholar
• SIEH HS, GANTHER HE: Acid-volatile seleniumformation catalyzed by glutathione reductase. Biochemistry (1975) 14:1632–1636.
   PubMed Web of Science ®Google Scholar
• FRENKEL GD, FALVEY D, MACVICAR C: Products of the reaction of selenite with intracellular sulfhydryl compounds. Biol Trace Elem. Res. (1991) 30:9–18.
   PubMed Web of Science ®Google Scholar
• HARRISON PR, LANFEAR J, WU L et al.: Chemopreventive and growth inhibitory effects of selenium. Biomed. Environ. Sci. (1997) 10:235–245.
   PubMedGoogle Scholar
• SPYROU G, BJORNSTEDT M, KUMAR S. et al.: AP-1 DNA-binding activity is inhibited by selenite and selenodiglutathione. FEBS Lett. (1995) 368:59–63.
   Google Scholar
• SPALLHOLZ JE: On the nature of selenium toxicity and carcinostatic activity. Free Rad. Biol. Med. (1994) 17:45–64.
   PubMed Web of Science ®Google Scholar
• BOPP BA, SONDERS RC, KESTERSON JW: Metabolic fateof selected selenium compounds in laboratory animals and man. Drug Metab. Rev. (1982) 13:271–318.
   PubMed Web of Science ®Google Scholar
• HOFFMAN, JL, MCCONNELL, KP, CARPENTER, DR:Aminoacylation of Escherichia coli methionine tRNA by selenomethionine. Biochim. Biophys. Acta (1970) 199:531.
   PubMed Web of Science ®Google Scholar
• REDMAN C, SCOTT JA, BAINES AT et al: Inhibitory effectof selenomethionine on the growth of three selected human tumor cell lines. Cancer Lett (IRELAND) (1998) 125:103–110.
   PubMed Web of Science ®Google Scholar
• Selenium. In: Trace elements in human nutrition and health. Geneva: World health Organization (1996):105–122.
   Google Scholar
• LEVANDER OA, BECK MA: Interacting nutritional and infectious etiologies of Keshan disease. Insights from coxsackie virus B-induced myocarditis in mice deficient in selenium or vitamin E. Biol. Trace Elem. Res. (1997) 56:5–21.
   Google Scholar
• BECK MA: Rapid genomic evolution of a non-virulentcoxsackievirus B3 in selenium-deficient mice. Biomed. Environ. Sci. (US) (1997) 10:307–315.
   PubMedGoogle Scholar
• SHAMBERGER RJ, FROST DV: Possible protective effectof selenium against human cancer. Can. Med. Assoc. J. (1969) 100:682.
   PubMed Web of Science ®Google Scholar
• •Thirty years ago, this prescient article suggested the possibility that selenium may exert a protective effect against cancer.
   Google Scholar
• SCHRAUZER GN, THEAD WJ: Interpretation of the methylene blue reduction test of human plasma and the possible cancer protecting effect of selenium. Experientia (1971) 27:1069–1071.
   PubMedGoogle Scholar
• COMBS GF JR: Selenium and cancer. In: Biochemistry and Molecular Biology of Selenium Wang Z, (Ed.), Chinese Academy of Science, Beijing, China (1995).
   Google Scholar
• IP C, MEDINA D: Current concept of selenium and mammary tumorigenesis. In: Cellular and Molecular Biology of Breast Cancer. Medina D, Kidwell W, Heppner G, Anderson EP, (Eds.), Plenum Press, New York, USA (1987)479.
   Google Scholar
• SCHRAUZER GN, WHITE DA, SCHNEIDER CJ: Cancer mortality correlation studies, III. Bioinorganic Chem. (1977) 7:23–34.
   PubMedGoogle Scholar
• CLARK LC, CANTOR KP, ALLAWAY WH: Selenium in forage crops and cancer mortality in US counties. Arch. Environ. Health (1991) 46:37–42.
   PubMed Web of Science ®Google Scholar
• SCHRAUZER, GN: Selenium: Mechanistic aspects of anticarcinogenic action. Biol. Trace Elem. Res. (1992) 33:51–62.
   PubMed Web of Science ®Google Scholar
• GUPTA S, NARANG R, KRISHNASWAMI K et al.: Plasma selenium level in cancer patients. Indian J. Cancer (1994) 31:192–197.
   PubMedGoogle Scholar
• BURKE KE, COMBS GF JR, GROSS EGBKC et al.: The effects of topical and oral L-selenomethionine on pigmentation and skin cancer induced by ultraviolet irradiation. Nutr. Cancer (1992) 17:123–137.
   PubMed Web of Science ®Google Scholar
• GEY KF: Vitamins E plus C and interacting conutrients required for optimal health. A critical and constructive review of epidemiology and supplementation data regarding cardiovascular disease and cancer. Biofac-tors (1998) 7:113–174.
   Google Scholar
• •This is a very useful review of a large body of information regarding the beneficial effects of dietary anti-oxidants.
   Google Scholar
• BLOT WJ: Vitamin/mineral supplementation and cancer risk: international chemoprevention trials. Proc. Soc. Exp. Biol. Med. (1997) 216:291–296.
   PubMed Web of Science ®Google Scholar
• SCHWENKE DC, BEHR SR: Vitamin E combined with selenium inhibits atherosclerosis in hypercholestero-lemic rabbits independently of effects on plasma cholesterol concentrations. J. Biol. Chem. (1998) 273:23039–23045.
   PubMedGoogle Scholar
• CHEN C; ZHOU J; XU H et al.: Effect of selenium supple-mentation on mice infected with LP-BM5 MuLV, a murine AIDS model. Biol. Trace Elem. Res. (1997) 59:187–193.
   Google Scholar
• AASETH J, HAUGEN M, FRRE 0: Rheumatoid arthritis and metal compounds - perspectives on the role of oxygen radical detoxification. Analyst (1998) 123:3–6.
   PubMed Web of Science ®Google Scholar
• YANG GQ, XIA YM: Studies on human dietary require-ments and safe range of dietary intakes of selenium in China and their application in the prevention of related endemic diseases. Biomed. Environ. Sci. (1995) 8:187–201.
   PubMedGoogle Scholar
• PATTERSON BH, LEVANDER OA: Naturally occurring selenium compounds in cancer chemoprevention trials: a workshop summary. Cancer EpidemioL Biomarkers Prey. (1997) 6:63–69.
   PubMed Web of Science ®Google Scholar
• HERCBERG S, GALAN P, PREZIOSI P et al.: Backgroundand rationale behind the SU.VI.MAX Study, a prevention trial using nutritional doses of a combina-tion of antioxidant vitamins and minerals to reduce cardiovascular diseases and cancers. Int. J. Vitam. Nutr. Res. (1998) 68:3–20.
   Google Scholar
• PARNHAM MJ, GRAF E: Pharmacology of synthetic organic selenium compounds. Prog. Drug Res. (1991) 36:9–47.
   PubMedGoogle Scholar
• SHAMBERGER RJ: Synthetic forms of selenium and their chemotherapeutic uses. In: Biochemistry of selenium. Shamberger RJ (Ed.), Plenum, New York (1983):273–310.
   Google Scholar
• KLAYMAN DL: Selenium compounds as potential therapeutic agents. In: Organic selenium compounds: their chemistry and biology. Klayman DL, Gunther WH, (Eds), Wiley, New York (1973):727–61.
   Google Scholar
• PARNHAM MJ: The pharmaceutical potential of selenium. Pharmaceut. News (1996) 3:7–10.
   Google Scholar
• MAY SW, PHILLIPS SR, MUELLER PW: Dopamine-b-Hydroxylase: Comparative Specificities and Mechanisms of the Oxygenation Reactions. J. Biol. Chem. (1981) 256:8470–8475.
   PubMed Web of Science ®Google Scholar
• MAY SW, PHILLIPS SR, MUELLER PW et al.: Dopamine-9-Hydroxylase: Demonstration of Enzymatic Ketonization of the Product Enantiomer, S-Octopamine. J. Biol. Chem. (1981) 256:2258–2261.
   PubMed Web of Science ®Google Scholar
• MAY SW, PHILLIPS SR: Asymmetric Sulfoxidation by Dopamine-9-Hydroxylase, An Oxygenase Heretofore Considered Specific for Methylene Hydroxylation. J. Amer. Chem. Soc. (1980) 102:5981–5983.
   Web of Science ®Google Scholar
• PADGETTE SR, WIMALASENA K, HERMAN HH et al.: Olefin Oxygenation and N-Dealkylation by Dopamine-B-Monoxygenase: Catalysis and Mechanism-Based Inhibition. Biochem. (1985) 24:5826–5839.
   PubMed Web of Science ®Google Scholar
• WIMALASENA K, MAY SW: Mechanistic Studies on Dopamine-9-MonooxygenaseCatalysis:N-Dealkylation and Mechanism-Based Inhibition by Benzylic Nitrogen-Containing Compounds. Evidence for a Single Electron Transfer Mechanism. J. Amer. Chem. Soc. (1980) 109:4036–4046.
   Google Scholar
• SIRIMANNNE SR, HERMAN HH, MAY SW: Interaction ofDopamine-13-Monooxygenase with Substituted Imidazoles and Pyrazoles: Catalysis and Inhibition. Biochem. J. (1987) 242:227–233.
   PubMed Web of Science ®Google Scholar
• MAY SW, HERMAN HH, ROBERTS SF et a/Ascorbatedepletion as a consequence of product recycling during dopamine b-monooxygenase catalyzed selenoxidation. Biochem. (1987) 26:1626–1632.
   PubMed Web of Science ®Google Scholar
• MAY SW, WIMALASENA K, HERMAN HH et al.: Novelantihypertensives targeted at dopamine b-monooxygenase: turnover-dependent cofactor depletion by phenyl aminoethyl selenide. J. Med. Chem. (1988) 31:1066–1068.
   PubMed Web of Science ®Google Scholar
• WIMALASENA K, HERMAN HH, MAY SW: Effects of dopamine b-monooxygenase substrate analogs on ascorbate levels and norepinephrine synthesis in adrenal chromaffin granule ghosts. J. Biol. Chem. (1989) 264:124–130.
   PubMed Web of Science ®Google Scholar
• HERMAN HH, WIMALASENA K, FOWLER LC et al.: Demonstration of the ascorbate dependence of membrane-bound dopamine b-monooxygenase in adrenal chromaffin granule ghosts. J. Biol. Chem. (1988) 263:666–672.
   PubMed Web of Science ®Google Scholar
• MAY SW, YOUNG FK, POWERS JL et al.: Mechanism-based inactivation of dopamine beta-monooxygenase in adrenal chromaffin cells. Biochem. Biophys. Res. Commun. (1996) 228:278–284.
   PubMed Web of Science ®Google Scholar
• POLLOCK SH, HERMAN HH, FOWLER LC et al.: Demonstration of the antihypertensive activity of phenyl-2-aminoethyl selenide. j Pharm. Exp. Therap. (1988) 246:227–234.
   PubMed Web of Science ®Google Scholar
• RIMMER SJ, CHURCH MK: The pharmacology and mechanism of actions of histamine Hl-antagonists. Clin. Exper. Allergy (1990) 20 (Supp1.2):3–17.
   Google Scholar
• GILMAN AG, RALL TW, NIES AS et al.: Goodman andGilman 's Pharmacological Basis of Therapeutics. 8th ed. McGraw-Hill, Inc. New York (1990):159.
   Google Scholar
• NADELMANN J, FRISHMAN WH: Clinical use of beta-adrenoceptor blockade in systemic hyperten-sion. Drugs (1990) 39:862–876.
   PubMed Web of Science ®Google Scholar
• MAY SW, WANG L, GILL MM et al.: An orally active selenium-based antihypertensive agent with restricted CNS permeability. J. Pharm. Exp. Therap. (1997) 283:470–477.
   PubMed Web of Science ®Google Scholar
• ••This paper, from the present author's laboratory, describesthe first orally-active selenium-based antihypertensive compound ever reported. Rational biochemical design, as well as inductively coupled plasma/mass spectroscopy and operant behavior analyses, were utilised to develop a selenium-based compound which exhibits both oral activity and restricted CNS permeability.
   Google Scholar
• ARSCOTT LD, GROMER S, SCHIRMER RH et al.: The mechanism of thioredoxin reductase from human placenta is similar to the mechanisms of lipoamide dehydrogenase and glutathione reductase and is distinct from the mechanism of thioredoxin reductase from Escherichia co& Proc. Natl. Acad. Sci. USA (1997) 94:3621–2626.
   PubMed Web of Science ®Google Scholar
• BJORNSTEDT M, KUMAR S, BJORKHEM L et al.: Seleniumand the thioredoxin and glutaredoxin systems. Biomed. Environ. Sci. (1997) 10:271–279.
   PubMedGoogle Scholar
• TAMURA T, STADTMAN TC: A new selenoprotein fromhuman lung adenocarcinoma cells: purification, properties, and thioredoxin reductase activity. Proc. Natl. Acad. Sci. USA (1996) 93:1006–1011.
   PubMed Web of Science ®Google Scholar
• POWIS G, OBLONG JE, GASDASKA PY et al.: The thiore-doxin/thioredoxin reductase redox system and control of cell growth. Oncol. Res. (1994) 6:539–544.
   PubMed Web of Science ®Google Scholar
• BIGUET C, WAKASUGI N, MISHAL Z: Thioredoxin increases the proliferation of human B-cell lines through a protein kinase C-dependent mechanism. J. Biol. Chem. (1994) 269:28865–28870.
   PubMed Web of Science ®Google Scholar
• GASDASKA JR, BERGGREN M, POWIS G: Cell growth stimulation by the redox protein thioredoxin occurs by a novel helper mechanism. Cell Growth Differ. (1995) 6:1643–1650.
   PubMedGoogle Scholar
• ENGMAN L, COTGREAVE I, ANGULO M et al.: Diarylchalcogenides as selective inhibitors of thioredoxin reductase and potential antitumor agents. Anti-Cancer Res. (1997) 17:4599–4605.
   PubMed Web of Science ®Google Scholar
• •Several organoselenium and organotellurium thioredoxin reductase inhibitors were shown to inhibit the growth of human cancer cells in culture.
   Google Scholar
• GALLEGOS A; BERGGREN M; GASDASKA JR et al.: Mechanisms of the regulation of thioredoxin reductase activity in cancer cells by the chemopreven-tive agent selenium. Cancer Res. (1997) 57:4965–4970.
   Google Scholar
• GROMER S, ARSCOTT LD, WILLIAMS CH Jr et al.: Human placenta thioredoxin reductase. Isolation of the selenoenzyme, steady state kinetics, and inhibition by therapeutic gold compounds. J. Biol. Chem. (1998) 273:20096–20101.
   Google Scholar
• ••Human thioredoxin reductase is inhibited by organic goldcompounds commonly used in the treatment of rheumatoid arthritis, and this inhibition likely entails interaction of the gold atom with the C-terminal Cys-495/SeCys-496 moiety of the enzyme.
   Google Scholar
• WAKASUGI N, TAGAYA Y, WAKASUGI H et al: Adult T-cell leukemia-derived factor/thioredoxin, produced by both human T-lymphotropic virus Type I- and Epstein-Barr virus-transformed lymphocytes, acts as an autocrine growth factor and synergizes with interleukin 1 and interleukin 2. Proc. Natl. Acad. Sci. USA (1990) 87:8282–8286.
   PubMed Web of Science ®Google Scholar
• COONEY DA, JAYARAM HN, GEVEYEHU G et al.: The conversion of 2-beta-D-ribofuranosyl-thiazole-4-carboxamide to an analogue of NAD with potent IMP dehydrogenase-inhibitory properties. Biochem. Pharmacol. (1982) 31:2133–2136.
   PubMed Web of Science ®Google Scholar
• LEE H, PAWLAK K, NGUYEN BT et al.: Biochemical differ-ences among four inosinate dehydrogenase inhibi-tors, mycophenolic acid, ribavirin, tiazofurin, and selenazofurin, studied in mouse lymphoma cell culture. Cancer Res. (1985) 45:5512–5520.
   PubMed Web of Science ®Google Scholar
• STREETER DG, ROBINS RK: Comparative in vitro studies of Tiazofurin and a selenazole analog. Biochem. Biophys. Res. Commun. (1983) 115:544–550.
   PubMed Web of Science ®Google Scholar
• O'DWYER PJ, SHOEMAKER DD, JAYARAM HN et al: Tiazofurin: a new antitumor agent. Invest. New Drugs (1984) 2:79–84.
   PubMed Web of Science ®Google Scholar
• GHAREHBAGHI K; SREENATH A; HAO Z et al.: Comparison of biochemical parameters of benzamide riboside, a new inhibitor of IMP dehydrogenase, with tiazofurin and selenazofurin. Biochem. Pharmacol. (1994) 48:1413–1419.
   Google Scholar
• TRICOT G, WEBER G: Biochemically targeted therapy of refractory leukemia and myeloid blast crisis of chronic granulocytic leukemia with Tiazofurin, a selective blocker of inosine 50-phosphate dehydroge-nase activity. Anti-Cancer Res. (1996) 16:3341–3347.
   PubMed Web of Science ®Google Scholar
• KIRSI JJ; NORTH JA; MCKERNAN PA et al.: Broad-spectrum antiviral activity of 2-beta-D-ribofuranosylselenazole-4-carboxamide, a new antiviral agent. Antimicrob. Agents Chemother. (1983) 24: 353–361.
   Google Scholar
• ROBINS RK; REVANKAR GR; MCKERNAN PA et al.: The importance of IMP dehydrogenase inhibition in the broad spectrum antiviral activity of ribavirin and selenazofurin. Adv. Enzyme Regul (1985) 24:29–43.
   Google Scholar
• SID WELL RW, HUFFMAN JH, BARNARD DL et al: Antiviral and immunomodulating inhibitors of experimentally-induced Punta Toro virus infections. Antiviral Res. (1994) 25:105–122.
   PubMed Web of Science ®Google Scholar
• FRANCHETTI P, CAPPELLACCI L, SHEIKHA GA et al.: Synthesis, structure, and antiproliferative activity of selenophenfurin, an inosine 50-monophosphate dehydrogenase inhibitor analogue of selenazofurin. J. Med. Chem (1997) 40:1731–1737.
   PubMed Web of Science ®Google Scholar
• YAMAGUCHI T, SANO K, TAKAKURA K et al: Ebselen in acute ischemic stroke: a placebo-controlled, double-blind clinical trial. Stroke (1998) 29:12–17.
   PubMed Web of Science ®Google Scholar
• TAKASAGO T, PETERS EE, GRAHAM DI et al.: Neuropro-tective efficacy of ebselen, an anti-oxidant with anti-inflammatory actions, in a rodent model of permanent middle cerebral artery occlusion. Br. J. Pharmacol. (1997) 122:1251–1256.
   PubMed Web of Science ®Google Scholar
• HOSHIDA S, AOKI K, NISHIDA M et al Effects of precon-ditioning with ebselen on glutathione metabolism and stress protein expression. J. Pharmacol. Exp.Ther. (1987) 218:1471–1475.
   Google Scholar
• JACOB C, MARET W, VALLEE BL: Ebselen, a selenium-containing redox drug, releases zinc from metallothionein. Biochem. Biophys. Res. Commun. (1998) 248:569–573.
   PubMed Web of Science ®Google Scholar
• COTGREAVE IA, JOHANSSON U; WESTERGREN G et al.: The anti-inflammatory activity of Ebselen but not thiols in experimental alveolitis and bronchiolitis. Agents Actions (1988) 24:313–319.
   Google Scholar
• •The well studied organoselenium compound, ebselen, inhibits Sephadex-induced lung oedema and infiltration of lymphocytes, basophils and eosinophils into the lung in rats.
   Google Scholar